Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
AIDX Catalyst Timeline
Dated clinical, regulatory and corporate events for 20/20 Biolabs, Inc.
Past FDA Catalysts and PDUFA Decisions
How AIDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
20/20 Biolabs, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AIDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bergman Alan B.Officer (Chief Financial Officer) | Grant/Award | 100,000 100,000 held | $0.00 | 04/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AIDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AIDX for Q2 2026. | ||||
Ownership Trends
AIDX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AIDX ranks across every disease it competes in
AIDX News
20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
20/20 BioLabs reported a 4.1% revenue increase to $1.36 million for the first nine months of 2026. The company secured a two-year cancer screening contract with Vermont, expected to boost revenue in Q4. However, third quarter revenue fell to $0.38 million, and net loss increased to $1.38 million, reflecting operational challenges.
Read more →REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026
20/20 BioLabs has called for stockholders to vote at the Special Meeting on December 9, 2026. Key proposals include authorization for a reverse stock split to meet Nasdaq's minimum bid price requirement. Stockholders of record as of October 20, 2026, can vote online or via phone. The Board encourages participation to ensure a quorum.
Read more →20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy
20/20 BioLabs will host an investor webinar on November 4, 2026, led by CEO Jonathan Cohen. The discussion will cover plans for expanding OneTest™ through licensing and acquisitions, FDA strategies, and initiatives for firefighter cancer screening. The company aims to enhance its commercial reach and address investor questions during the session.
Read more →20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
20/20 BioLabs, Inc. will participate in the Maxim Growth Summit 2026 on October 14, 2026, at the Hard Rock Hotel New York. CEO Jonathan Cohen and CFO Alan Bergman will hold one-on-one meetings with institutional investors. The summit aims to showcase the company's AI-powered blood tests for early cancer and chronic disease detection.
Read more →20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
20/20 BioLabs is hosting an investor webinar on October 7, 2026, to discuss the implications of a recent FDA advisory committee vote on multi-cancer early detection tests. CEO Jonathan Cohen will outline the company's new OneTest™ franchise model and the preliminary interest from laboratories. The webinar aims to provide insights into regulatory strategies and new funding initiatives for cancer screening.
Read more →20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs has rescheduled its investor webinar to September 2, 2026, at 2:00 p.m. ET. CEO Jonathan Cohen will discuss the company's record revenue for OneTest™ and insights from the Next Generation Dx Summit. The webinar will cover the company's growth strategies and the evolution of its testing platform, along with a Q&A session.
Read more →20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs will host an investor webinar on September 2, 2026, to discuss its record revenue and commercial strategies. CEO Jonathan Cohen will highlight the company's second quarter results, including a 47.1% increase in OneTest™ revenue. The webinar will also cover key insights from the Next Generation Dx Summit and the evolution of the OneTest™ platform.
Read more →20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
20/20 BioLabs reported strong financial results for Q2 2026, with OneTest™ revenue reaching $0.7 million, a 47% increase year-over-year. The company expanded its market reach and eliminated all convertible note debt, strengthening its cash position to $4.5 million. Despite a net loss of $1.5 million, the operational metrics indicate significant growth and improved profitability.
Read more →20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
20/20 BioLabs will host an investor webinar on August 5, 2026, to discuss insights from its recent East Asia business development tour. CEO Jonathan Cohen will cover the company's participation in BIO Asia-Taiwan and its strategic meetings in Taipei, Tokyo, and Seoul. The webinar will also address the company's East Asia roll-up strategy and opportunities for commercialization.
Read more →20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs participated in BIO Asia-Taiwan and held strategic meetings in East Asia to explore acquisition and partnership opportunities. The company aims to enhance its mission of early disease detection through collaborations with local firms. CEO Jonathan Cohen emphasized the importance of these relationships for achieving Medicare reimbursement for their multi-cancer early detection test by 2028.
Read more →20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
20/20 BioLabs has entered a standstill agreement with Streeterville Capital regarding its Series E Convertible Preferred Stock. This agreement restricts the conversion of preferred stock into common stock unless certain price thresholds are met, thereby mitigating potential dilution. The agreement is effective for 120 days, after which normal conversion activities may resume.
Read more →20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
20/20 BioLabs presented its strategy for advancing OneTest™ for Cancer during an investor webinar. The company aims to position the test for Medicare reimbursement under new legislation for multi-cancer early detection blood tests. While the approach shows promise, it faces significant regulatory hurdles, including the need for FDA authorization and CMS coverage determinations.
Read more →20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
20/20 BioLabs has announced a new monthly investor webinar series starting July 1, 2026. The initiative aims to enhance transparency and communication with shareholders by providing direct access to management. Each session will last approximately 45 minutes and will include updates on the company's progress. Attendees will receive a promotional discount for a blood test.
Read more →20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
20/20 Biolabs is preparing for potential Ebola and Hantavirus testing in response to recent outbreaks. Drawing on its COVID-19 testing experience, the company is developing contingency plans and engaging with global PCR test kit developers. This proactive approach aims to ensure readiness for any surge in testing demands, although no regulatory authorization has been granted yet.
Read more →BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026
20/20 BioLabs, Inc. (AIDX) reported its first quarter financial results for 2026, highlighting a decrease in revenue to $0.4 million. The company noted a significant $5.0 million private placement aimed at strengthening its cash position to $4.2 million. Noteworthy operational progress includes new distribution agreements and the launch of the OneTest for Longevity product. Despite a loss of $2.2 million during the quarter, the projected expansion of firefighter cancer screening initiatives is expected to drive future revenue growth.
Read more →20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
20/20 BioLabs, Inc. reported its financial results for FY 2025, highlighting a 17% revenue increase to $2.0 million and a significant gross profit rise of 68%. The company's gross margin expanded notably, driven by the success of its OneTest suite of products in the expanding Multi-Cancer Early Detection (MCED) market. Despite improvements, the company also recorded a net loss of $3.7 million. Future growth is anticipated through state-funded cancer screening initiatives and new offerings such as the OneTest for Longevity.
Read more →Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
20/20 BioLabs announced that 18 Maryland fire departments will receive over $520,000 for cancer screenings using their OneTest™ multi-cancer early detection blood test. This funding, part of a state initiative, aims to screen over 1,400 firefighters, highlighting the growing support for innovative cancer detection. The initiative reflects a 225% increase in funding compared to the previous year.
Read more →20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
20/20 BioLabs has entered an exclusive U.S. license agreement with ROKIT Healthcare to incorporate a chronic kidney disease (CKD) prediction algorithm into its Longevity Platform. This partnership aims to enhance disease-risk assessment tools, potentially improving therapeutic outcomes for patients. The agreement also includes provisions for ROKIT to commercialize the platform in Korea and other East Asian markets.
Read more →20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
20/20 BioLabs has launched the OneTest for Longevity, a blood test that uses IBM's AI technology to assess chronic disease risks. This test analyzes inflammatory biomarkers and provides personalized dietary recommendations. The collaboration with DAISource aims to enhance healthcare applications through AI. However, the test is not FDA approved.
Read more →20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
20/20 BioLabs, Inc. will hold a virtual investor webinar on February 26, 2026, at 2:00 p.m. ET. CEO Jonathan Cohen will discuss the company's recent Nasdaq listing and its AI-powered blood tests, including the OneTest for Cancer and the upcoming OneTest for Longevity. A Q&A session will follow the presentation.
Read more →